Immunofluorescent microscopy antibodies. by Piotr Pawel Janas (17847034)

Subjects:

The difference in the aggregation-independent amyloid removal rate between NC participants and AD patients translates into a much greater relative difference in intratissue amyloid... by Dmitry V. Zaretsky (14034897)

Getting research into practice matrix. by Ghasem Abedi (3387341)

Subjects:

Baseline compliance with the best practice for audit criteria (%). by Ghasem Abedi (3387341)

Subjects:

The project steps. by Ghasem Abedi (3387341)

Subjects:

Audit criteria, sample, and approach to the measurement of compliance with best practice. by Ghasem Abedi (3387341)

Subjects:

Compliance with the best practice criteria in follow-up audit compared to baseline audit (%). by Ghasem Abedi (3387341)

Subjects:

The members of team. by Ghasem Abedi (3387341)

Subjects:

Trends in the incidence of Cardiac Arrest (A), Mortality following Cardiac Arrest (B), and ECMO Utilization for Cardiac Arrest (C). by Joseph Hadaya (11177635)

Subjects:

Factors associated with ECMO utilization among non-COVID-19 cardiac arrest patients treated from 2016-2020. by Joseph Hadaya (11177635)

Subjects:

Unadjusted and risk-adjusted outcomes among patients treated during the Pandemic time period stratified by presence of COVID-19 diagnosis. CI, confidence interval; COVID-19, Corona... by Joseph Hadaya (11177635)

Subjects:

Patient and hospital characteristics for non-COVID-19 cardiac arrest patients treated from 2016-2020 stratified by Pre-Pandemic and Pandemic time periods. ECMO, extracorporeal memb... by Joseph Hadaya (11177635)

Subjects:

Flow diagram of patients included in primary and secondary analyses. by Joseph Hadaya (11177635)

Subjects:

Unadjusted and risk-adjusted outcomes among non-COVID-19 cardiac arrest patients treated from 2016−2020, stratified by Pre-Pandemic and Pandemic time-periods. CI, confidence interv... by Joseph Hadaya (11177635)

Subjects:

Patient and hospital characteristics solely among those experiencing cardiac arrest during the Pandemic time period, stratified by presence of acute COVID-19 diagnosis. ECMO, extra... by Joseph Hadaya (11177635)

Subjects:

Overview of the training strategy we followed to train our models. by M. Taleb Albrijawi (18864346)

Fold change in humoral and cellular response magnitudes from RV305 week 2 to week 26. by LaTonya D. Williams (3140490)

Development of Melanocortin 4 Receptor Agonists by Exploiting Animal-Derived Macrocyclic, Disulfide-Rich Peptide Scaffolds by Edin Muratspahić (9578931)

Subjects:

List of <i>im</i> mitochondria genes showing more than 2-fold reduction as compared with TM-1 mitochondria genes when the NIL leaves incubated at 35°C air temperature for 3 days. by Hee Jin Kim (469168)

Cold sensitivity can be suppressed by increasing <i>fabA</i> expression. by Ashutosh K. Rai (18874704)